Prostate Cancer - Results from #920

ProstaMine: a bioinformatics tool for identifying subtype-specific co-alterations associated with aggressiveness in prostate cancer. May 16, 2024

The impact of prostate volume estimation on the risk-adapted biopsy decision based on prostate-specific antigen density and magnetic resonance imaging score. May 16, 2024

Pelvic exenteration for locally advanced and recurrent prostate cancer. May 16, 2024

Bellmunt risk score as a survival predictor in patients with metastatic castration-resistant prostate cancer. May 16, 2024

Androgen receptor splice variants drive castration-resistant prostate cancer metastasis by activating distinct transcriptional programs. May 15, 2024

Genetic Testing in Men With Metastatic Castration-Resistant Prostate Cancer. May 15, 2024

Prevalence of DNA-Repair Gene Mutations in Mexican Men with Prostate Cancer. May 15, 2024

Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial. May 15, 2024

A bicentric retrospective study of the correlation of EAU BCR risk groups with 18F-PSMA-1007 PET/CT detection in prostate cancer biochemical recurrence. May 15, 2024

Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study. May 15, 2024

Biochemical Response of <0.1 ng/ml Predicts Therapy-free Survival of Prostate Cancer Patients following Prostate-specific Membrane Antigen-targeted Salvage Surgery. May 15, 2024

Determinants of receipt of prostate cancer screening among men living with HIV enrolled in an urban HIV Clinic in the United States over the period of 2000-2020. May 14, 2024

Morphologic patterns observed in prostate biopsy cases with discrepant grade group and molecular risk classification. May 14, 2024

Robot-Assisted Radical Prostatectomy Performed with the Novel Hugo™ RAS System: A Systematic Review and Pooled Analysis of Surgical, Oncological, and Functional Outcomes. May 14, 2024

Contemporary Diagnosis of Very Low-risk Prostate Cancer in a Multihospital Health Care System. May 14, 2024

Efficacy of Poly(ADP-ribose) Polymerase Inhibitors by Individual Genes in Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer: A US Food and Drug Administration Pooled Analysis. May 14, 2024

ACSM1 and ACSM3 regulate fatty acid metabolism to support prostate cancer growth and constrain ferroptosis. May 14, 2024

High clonal diversity and spatial genetic admixture in early prostate cancer and surrounding normal tissue. May 14, 2024

Assessing the Clinical Utility of Published Prostate Cancer Polygenic Risk Scores in a Large Biobank Data Set. May 14, 2024

Differences in Tumor Gene Expression Profiles Between De Novo Metastatic Castration-sensitive Prostate Cancer and Metastatic Relapse After Prior Localized Therapy. May 14, 2024

Page 47 of 1437